ESSA Pharma Inc. Shares Details on Recent Developments with Supreme Court in British Columbia

ESSA Pharma Inc. Updates on Supreme Court Proceedings

In an important announcement on September 30, 2025, ESSA Pharma Inc. (NASDAQ: EPIX) revealed crucial developments regarding its pending application to the Supreme Court of British Columbia. The company is currently engaged in a transaction that involves merging with XenoTherapeutics Inc., a notable non-profit biotechnology foundation headquartered in Massachusetts.

The Supreme Court had issued an amended Interim Order that is relevant to this merger, which was finalized on September 25, 2025. This amended order has approved several key dates that will affect shareholders of ESSA Pharma. Notably, the company has scheduled a special meeting to discuss the business combination that will take place on October 3, 2025. This online event will provide shareholders an opportunity to weigh in on the transaction and make their voices heard.

ESSA is entitled to a period where shareholders can submit dissent notices until October 1, 2025. Additionally, the court has allocated October 7, 2025, for a hearing to determine approval of the merger arrangement. This series of meetings and deadlines sets a time-sensitive atmosphere for ESSA shareholders, emphasizing the significance of the upcoming events.

The special meeting on October 3 will be held at 2:00 PM Pacific Time and will be accessible via a live interactive webcast, making participation easier for shareholders regardless of their location. It's expected that the discussions will focus on ESSA's strategies moving forward and the benefits of the merger with XenoTherapeutics.

For context, XenoTherapeutics is committed to advancing the field of xenotransplantation through extensive research and innovation. The merger is aimed at combining efforts to accelerate medical advancements in this unique area of biotechnology. With this merger, ESSA Pharma hopes to leverage Xeno's resources and expertise to enhance its own development in addressing unmet medical needs, especially regarding therapies targeting prostate cancer.

As a company that previously focused on developing proprietary pharmaceutical therapies, the proposed combination signifies ESSA’s ambition to broaden its research horizons and tap into new therapeutic avenues. Adjustments to the original transaction terms were also filed in supplemental proxy materials submitted to regulatory bodies, ensuring transparency and compliance with necessary regulations.

As ESSA navigates through these pivotal changes, all eyes will be on the company's upcoming meetings. It represents not only a change for ESSA but potentially a significant shift in how both organizations can collaborate to innovate within the biopharmaceutical landscape. Stakeholders are advised to stay informed by reviewing proxy materials and updates as they are published, and to attend the special meeting to understand the implications of this transaction more thoroughly.

Updates pertinent to this merger and its potential impact continue to emerge; investors and interested parties can follow up closely by visiting ESSA's official website or the financial platforms where updates are provided. The integration with XenoTherapeutics holds promise for a future where clinical advancements in transplantation could become a reality, pushing the boundaries of medical science.